Bioton is First Polish Biotech Company to go Public


Warsaw - The first biotech company in the history of the Polish capital market is planning to make its debut at the Warsaw Stock Exchange (WGPW) at the end of this year. In late October 2004 the Polish Securities and Exchange Commission (PSEC) expressed its consent to admit the shares of Bioton S.A. to public trading.
Cash Injection
In addition to the existing 161.8 million shares to be divided into Series A and B shares with a nominal value of 1 zloty (Euro 0.24), 16.1 million new ones (Series C) with the same nominal value will be emitted. Since the book-building range per share has not yet been published, it remains to be seen how large the cash injection from the IPO will be. However, experts consider the percentage of newly issued shares - 10% of total stock - to be rather small. “No existing investors have any intentions to sell their shares during the first months after the IPO,” Piotr Rusiecki, deputy director at CA IB Financial Advisers, whose company organizes the IPO, told Warsaw Business Journal.
Biggest shareholders of Bioton are Pro-kom Investments (49.99%), followed by Swiss Nihonswi AG (15.43%), Bank Austria Creditanstalt AG (12.36%), and the Biotechnology and Antibiotics Institute, Warsaw (11.22%).
Bioton is manufacturing and distributing biotechnological products (recombin-ant human insulin under the brand name Gensulin) and generic drugs (mainly antibiotics). It is the only Polish manufacturer, and one of the few worldwide, of recom-binant human insulin, which accounts for some 40% of the companies sales. The production of antibiotics from the cephalo-sporine group accounts for 41% of its sales. Within the period of the first six months of the year 2004, the Bioton Group claims to have held about 7% in the insulin market in Poland behind Novo Nordisk A/S and Eli Lilly, a 14% share in the cephalosporine antibiotics market and a 60% share in the aminoglycoside antibiotics market (based on data by IMS Health). According to the Warsaw Business Journal Bioton hopes to raise its shares of the insulin market to 20 to 30% within a few years.
Ambitious Growth Plans
After a net profit of a1.9 million in 2003, Bioton forecasts a profit of Euro4.7 million for this year. The company aims at investing some Euro60 million until 2009 - 80% of which will be spent on R&D and on the expansion of the production facilities.
Bioton's basic strategic aim is to expand as a biotechnological company and to systematically increase the share of medicinal products based on substances produced by biosynthesis. The next phase will encompass the development, implementation of the production processes and introduction onto the market of subsequent recombin-ant protein substances. These substances will be applied to produce the company's own medicinal products and will also be offered to other pharmaceutical producers as precursors.



Polish antibody development and manufacturing specialist Mabion S.A. more than tripled its revenues in 2011 (€2.5m) compared to 2010 (€0.74m). The increase in turnover mainly resulted from stronger client demand for R&D services...



Polish company Bioton S.A (Warsaw) and Swiss-headquartered generics giant Actavis (Zug) have joined forces to shake up the €12bn world market for recombinant insulins and insulin analogues. At the end of January, Bioton Chairman...



Zug/Warsaw - The fourth largest generics producer and a polish biotech want to create a stir in the market for diabetes drugs. Swiss Actavis and Bioton from Warsaw announced that they have formed a joint venture company for the...



Krakow – Polish Selvita S.A., which offers preclinical drug development services to pharma companies, has been ranked as the No. 1 “Rising Star” of this year’s Fast50 contest. In the programme, analysts from Deloitte Technology...



Warsaw – Poland’s Bioton S.A. has announced it is investing €20m in a new production plant in Szczecin. The biotechnology company is planning to manufacture insulin injection devices in the facility. The project involves the...



Warsaw – Biotech experts want to make the development of pharmaceutical and medical innovations a priority in Poland. At the start of September, members of the Polish Technology Platform for Innovative Medicine recommended that...



Kraków – Selvita SA CEO Pawel Przewiezlikowski announced at the end of July that the Polish drug development and drug discovery service firm is close to achieving profitability. After bagging EUR3.7m through an IPO on Warsaw’s...



Warsaw – Researchers from Lodz and Poznan Universities say Poland needs to update its draft GMO law. “The national current legal situation is complicated,” Prof. Tomas Twardowski told EuroBiotechNews, stressing that while trade...



Krakow – Polish Selvita S.A. is going public. By May, the drug discovery specialist announced it had entered into definite agreements with investors to sell 2.7 million shares for a total of EUR3.75m, resulting in a market...



Szczecin/Greifswald – A team of physical chemists headed by Robert Hoylst from the Polish Academy of Science have improved a method for calculating the migration time of drugs or drug delivery devices introduced into the sol/gel...

Displaying results 1 to 10 out of 108

1-10 Next >

© 2007-2016 BIOCOM



Current issue

All issues

Product of the week


Stock list

All quotes


  • PLETHORA (UK)3.38 GBP12.67%
  • RENEURON (UK)3.50 GBP7.69%


  • KAROLINSKA (S)8.00 SEK-8.05%
  • NOVACYT (F)1.50 EUR-7.98%
  • UCB (B)62.79 EUR-7.55%


  • GENMAB (DK)1229.00 DKK28.0%
  • NICOX (F)10.97 EUR27.7%
  • GALAPAGOS (B)50.94 EUR26.4%


  • BIONOR PHARMA (N)0.69 NOK-24.2%
  • BIOCARTIS GROUP NV (B)8.20 EUR-24.1%
  • MOBERG PHARMA (S)38.40 SEK-23.6%


  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)28.20 SEK1900.0%
  • NICOX (F)10.97 EUR486.6%


  • BB BIOTECH (D)44.27 EUR-84.4%
  • BIOTEST (D)16.90 EUR-77.8%

No liability assumed, Date: 25.05.2016


All Events



Biomedica 2016

Basel (CH)

Chemspec Europe 2016